POM-V Prescription Required Companion Animal

Acecare 2mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Acepromazine

Form

Injection

Species

Cats Dogs

Manufacturer

Ecuphar NV

VMD MA No.

32742/4018

What it's used for

is approximately one-third of a suitable induction agent. AN: 01427/2024 & 01425/2024 Tranquilisation: acepromazine tranquilisation (ataraxy) involves a mo...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Acepromazine

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Acecare 2mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

is approximately one-third of a suitable induction agent.
AN: 01427/2024 & 01425/2024
Tranquilisation: acepromazine tranquilisation (ataraxy) involves a modification of
temperament which is not associated with hypnosis, narcosis or marked sedation.
This is achieved with low doses of acepromazine.
Sedation: at higher dose rates acepromazine is a sedative.

Premedication: 0.03 – 0.125 mg per kg bodyweight by intramuscular, subcutaneous
or slow intravenous injection.
Other uses: By intramuscular or subcutaneous injection 0.0625 - 0.125 mg per kg
bodyweight. Approximately equivalent to 0.625 – 1.25 ml of 2 mg/ml injection per 20
kg bodyweight. By intravenous injection - as for intramuscular, except that it is
recommended the injection is made slowly.
The maximum dose that should be given is 4 mg acepromazine per animal.
Normally single doses of acepromazine are administered (see section 3.3,
Contraindications).
Take adequate precautions to maintain sterility. Avoid the introduction of
contamination during use. Should any apparent growth or discolouration occur,
discard the product.
Do not exceed 40 broachings per vial.

Do not use in pregnant animals.
Do not use on a long term basis in individual animals.

Dogs and cats:
Undetermined frequency
(cannot be estimated from the
available data):
Arrhythmia
*
*
after rapid intravenous injection.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

None.

Special precautions for safe use in the target species:
Acepromazine is hypotensive. Particular care should therefore be taken in
hypovolaemic animals; rehydration should precede acepromazine administration.
Acepromazine may cause hypothermia due to depression of the thermoregulatory
centre and peripheral vasodilation.
In some dogs, particularly Boxers and other short-nosed breeds, spontaneous
fainting or syncope may occur due to sinoatrial block caused by excessive vagal
tone. An attack may be precipitated by an injection of acepromazine, so a low dose
should be used.
Where there is a history of this type of syncope, or if it is suspected because of
excessive sinus arrhythmia, it may be advantageous to control the dysrhythmia with
atropine given just before the acepromazine.
Large breeds: It has been noted that large breeds of dogs are particularly sensitive to
acepromazine and the minimum dose possible should be used in these breeds.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Care should be taken when handling and administering this product to avoid
exposure.
This product contains a potent sedative. Take precautions to avoid accidental
injection. In case of accidental self-injection, seek medical advice immediately and
AN: 01427/2024 & 01425/2024
show the package leaflet or the label to the physician but DO NOT DRIVE as
sedation may occur. Symptomatic treatment may be required.
Avoid contact with eyes. If accidental eye contact occurs, flush gently with fresh
running water for 15 minutes and seek medical advice if any irritation persists.
In the event of accidental skin contact wash the contaminated area with large
amounts of soap and water. Medical advice should be sought if irritation persists.
Wash hands and exposed skin thoroughly after use.
Special precautions for the protection of the environment:
Not applicable.

Acepromazine is additive to the actions of other depressants and will potentiate
general anaesthesia (see section 3.2, indications for use). Do not use this product in
conjunction with organophosphates and/or procaine hydrochloride, as it may
enhance activity and potential toxicity.
AN: 01427/2024 & 01425/2024

Do not store above 25
o
C.
Keep the vial in the outer carton in order to protect from light.
Following withdrawal of the first dose, use remainder of the product within 28 days.
Discard unused material.

Not applicable.
AN: 01427/2024 & 01425/2024

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.